These remarkable effects on oxygen delivery and blood composition have sparked discussions about the potential applicability of SGLT2 inhibitors in patients with HF with preserved ejection fraction (HFpHF) [46]. The gene discussed is SLC5A2; the disease is hydrops fetalis.